Edwards Lifesciences Co. (NYSE:EW – Get Free Report) VP Daveen Chopra sold 1,500 shares of the stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $76.69, for a total transaction of $115,035.00. Following the completion of the transaction, the vice president now owns 23,950 shares in the company, valued at $1,836,725.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Edwards Lifesciences Trading Up 2.4 %
Shares of NYSE:EW opened at $77.83 on Wednesday. The firm has a market cap of $47.31 billion, a price-to-earnings ratio of 34.44, a PEG ratio of 4.11 and a beta of 1.02. Edwards Lifesciences Co. has a 12 month low of $67.13 and a 12 month high of $98.35. The company’s fifty day simple moving average is $85.48 and its 200 day simple moving average is $84.19. The company has a quick ratio of 2.30, a current ratio of 3.15 and a debt-to-equity ratio of 0.09.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Wednesday, July 26th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.51 billion. Edwards Lifesciences had a net margin of 24.56% and a return on equity of 25.43%. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 earnings per share. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.55 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on EW. Jefferies Financial Group increased their price objective on shares of Edwards Lifesciences from $103.00 to $107.00 and gave the company a “buy” rating in a report on Tuesday, July 25th. StockNews.com started coverage on shares of Edwards Lifesciences in a report on Thursday, August 17th. They issued a “buy” rating on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $102.00 target price on shares of Edwards Lifesciences in a report on Friday, July 14th. 58.com reiterated a “reiterates” rating on shares of Edwards Lifesciences in a report on Tuesday, June 27th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $96.00 target price on shares of Edwards Lifesciences in a report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $92.68.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
- Five stocks we like better than Edwards Lifesciences
- Are Stock Buybacks Good for the Average Investor?
- 3 Inexpensive Mid Cap Tech Stocks With Good Growth Prospects
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- 3 Reasons the Dick’s Sporting Goods Selloff Is a Steal
- What is a Stock Market Index and How Do You Use Them?
- Foot Locker Stock Takes a Big Hit…Is It a Retail Bargain?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.